Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 194

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Programmed cell death‐1 (PD‐1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell–intrinsic PD‐1

Li, Hui, Li, Xiaoqiang, Liu, Shuang, Guo, Lei, Zhang, Bo, Zhang, Jubo, Ye, Qinghai · 2017 · Hepatology

Abstract

Inhibitors of programmed cell death 1 (PD‐1) administered as single agents have resulted in durable tumor regression in advanced cancer patients. However, only a minority of cancer patients respond to anti‐PD‐1 immunotherapy. Here, we show that PD‐1 expression in hepatocellular carcinoma promotes tumor growth independently of adaptive immunity. Knockdown of PD‐1 suppresses tumor growth, whereas PD‐1 overexpression enhances tumorigenesis in immunodeficient xenografted mice. Mechanistically, PD‐1 binds the downstream mammalian target of rapamycin effectors eukaryotic initiation factor 4E and ribosomal protein S6, thus promoting their phosphorylation. Moreover, combining mammalian target of rapamycin inhibition with anti‐PD‐1 antibody treatment results in more durable and synergistic tumor regression than either single agent alone, each of which presents only modest efficacy. Conclusion: Targeting mammalian target of rapamycin pathways in combination with PD‐1 may result in increased antitumor efficacy in cancer patients. (H epatology 2017;66:1920–1933)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.29360

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

Metadata

Authors
Li, H., Li, X., Liu, S., Guo, L., Zhang, B., Zhang, J., & Ye, Q.
Venue
Hepatology
Published
2017-11-20
Volume
66
Issue
6
Pages
1920-1933
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W2737207041
Cited by
194
References
12
FWCI
6.03
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.